The overexpression of DNMT3B is common to many cancers and has been associated with poor clinical outcomes in hepatocellular carcinoma (Lai et al., 2019), oral cancer (Chen et al., 2014), esophageal carcinoma (Chen et al., 2012), and triple-negative breast cancer (So et al., 2022). This evidence concerns the gene DNMT3B and cancer.